EMA Application withdrawn: Cylatron (peginterferon alfa-2b) — SP Europe

View source ↗

Summary

European Medicines Agency report indicates withdrawal of the application for Cylatron (peginterferon alfa-2b) for melanoma by SP Europe.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cylatron (peginterferon alfa-2b)

Snippet

Status: Application withdrawn. Therapeutic area: Melanoma. MAH: SP Europe. Decision date: 31/12/2009